# GLP-1s for $50 a Month? 14 Million Medicare Recipients May Be Eligible
Up to 14 million Medicare beneficiaries now have access to glucagon-like peptide-1 (GLP-1) receptor agonist medications at a capped price of $50 per month. This marks a substantial shift in affordability for drugs like semaglutide and tirzepatide, which previously cost hundreds of dollars monthly for many seniors.
The policy expansion comes as Medicare continues negotiating drug prices under the Inflation Reduction Act. GLP-1 medications treat type 2 diabetes and, increasingly, are prescribed for weight management. The $50 monthly cap applies to eligible Medicare Part D enrollees with diabetes diagnoses.
For Medicare beneficiaries managing type 2 diabetes, this pricing change removes a significant barrier. Many seniors previously rationed doses or skipped medications due to cost. The lower price point brings these medications within reach for fixed-income populations.
Eligibility requires Medicare Part D enrollment and a documented type 2 diabetes diagnosis. Beneficiaries should verify their specific plan coverage, as not all Part D plans offer identical formularies. Those prescribed GLP-1 medications should contact their insurance provider or pharmacist to confirm whether their drug falls under the $50 cap.
The expansion reflects growing recognition that GLP-1s address both metabolic disease and obesity in aging populations. Obesity affects nearly 42 percent of adults over 60, and type 2 diabetes prevalence increases with age. Making these medications affordable helps more seniors access evidence-based treatments.
Healthcare providers should discuss coverage options with Medicare patients who might benefit from GLP-1 therapy. Those currently paying higher prices may find relief by reviewing their plans or speaking with their pharmacy about available options.